Cochrane · systematic review · CD008394
Interventions for treating leg ulcers in people with sickle cell disease
Martí-Carvajal, AJ, Knight-Madden, JM, Martinez-Zapata, MJ · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
42
current version
GRADE rated
10
No studies
30
Included studies
NR
No studies 30 · 71.4%Ungraded 2 · 4.8%Very low 10 · 23.8%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyIsoxsuprine compared with placebo for leg ulcers in people with sickle cell disease
Population: individuals with sickle cell disease and a leg ulcer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete leg ulcer closure (defined as 100% epithelization or skin closure without drainage) Isoxsuprine vs placebo | RR 1.2 [0.4, 3.62] | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision |
Time to ulcer closure ‐ not reported Isoxsuprine vs placebo | no estimate extracted | NR | No studies |
Change in ulcer size (surface area or volume) Isoxsuprine vs placebo | no estimate extracted | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision |
Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported Isoxsuprine vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Isoxsuprine vs placebo | no estimate extracted | NR | No studies |
Amputation ‐ not reported Isoxsuprine vs placebo | no estimate extracted | NR | No studies |
Adverse events ‐ not reported Isoxsuprine vs placebo | no estimate extracted | NR | No studies |
Arginine butyrate plus standard care alone compared with standard care alone for leg ulcers in people with sickle cell disease
Population: individuals with sickle cell disease and a leg ulcer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete leg ulcer closure (defined as 100% epithelization or skin closure without drainage) Arginine butyrate plus standard care alone vs standard care alone | RR 3.72 [0.9, 15.35] | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Time to ulcer closure ‐ not reported Arginine butyrate plus standard care alone vs standard care alone | no estimate extracted | NR | No studies |
Change in ulcer size (surface area or volume) Arginine butyrate plus standard care alone vs standard care alone | no estimate extracted | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported Arginine butyrate plus standard care alone vs standard care alone | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Arginine butyrate plus standard care alone vs standard care alone | no estimate extracted | NR | No studies |
Amputation ‐ not reported Arginine butyrate plus standard care alone vs standard care alone | no estimate extracted | NR | No studies |
Adverse events Arginine butyrate plus standard care alone vs standard care alone | no estimate extracted | 1 study · 23 participants | Ungraded |
Propionyl‐L‐carnitine compared with placebo for leg ulcers in people with sickle cell disease
Population: individuals with sickle cell disease and a leg ulcer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete leg ulcer closure (defined as 100% epithelization or skin closure without drainage) ‐ not reported Propionyl‐L‐carnitine vs placebo | no estimate extracted | NR | No studies |
Time to ulcer closure ‐ not reported Propionyl‐L‐carnitine vs placebo | no estimate extracted | NR | No studies |
Change in ulcer size (surface area or volume) Propionyl‐L‐carnitine vs placebo | no estimate extracted | 1 study · 15 participants | Very low Downgraded: risk of bias, imprecision |
Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported Propionyl‐L‐carnitine vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Propionyl‐L‐carnitine vs placebo | no estimate extracted | NR | No studies |
Amputation ‐ not reported Propionyl‐L‐carnitine vs placebo | no estimate extracted | NR | No studies |
Adverse events ‐ not measured Propionyl‐L‐carnitine vs placebo | no estimate extracted | NR | No studies |
RGD peptide matrix compared with placebo for leg ulcers in people with sickle cell disease
Population: individuals with sickle cell disease and leg ulcer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete closureUlcer area was determined by computerized planimetry RGD peptide matrix vs placebo | RR 0.4 [0.15, 1.04] | 1 study · 55 participants | Very low Downgraded: risk of bias, imprecision |
Time to ulcer closure ‐ not reported RGD peptide matrix vs placebo | no estimate extracted | NR | No studies |
Change in size ulcers healed ‐ not reported RGD peptide matrix vs placebo | no estimate extracted | NR | No studies |
Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported RGD peptide matrix vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not reported RGD peptide matrix vs placebo | no estimate extracted | NR | No studies |
Amputation ‐ not reported RGD peptide matrix vs placebo | no estimate extracted | NR | No studies |
Adverse events RGD peptide matrix vs placebo | RR 0.76 [0.5, 1.17] | 1 study · 55 participants | Very low Downgraded: risk of bias, imprecision |
Solcoseryl compared with antiseptic agent for leg ulcers in people with sickle cell disease
Population: individuals with sickle cell disease and leg ulcer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete leg ulcer closure ‐ not reported Solcoseryl vs antiseptic agent | no estimate extracted | NR | No studies |
Time to closure ‐ not reported Solcoseryl vs antiseptic agent | no estimate extracted | NR | No studies |
Change in ulcer size (surface area or volume) Solcoseryl vs antiseptic agent | no estimate extracted | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported Solcoseryl vs antiseptic agent | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Solcoseryl vs antiseptic agent | no estimate extracted | NR | No studies |
Amputation ‐ not reported Solcoseryl vs antiseptic agent | no estimate extracted | NR | No studies |
Adverse events Solcoseryl vs antiseptic agent | no estimate extracted | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
Duoderm® (hydroactive dressing) compared with antiseptic agent for leg ulcers in people with sickle cell disease
Population: individuals with sickle cell disease and leg ulcer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete leg ulcer closure ‐ not reported Duoderm® (hydroactive dressing) vs antiseptic agent | no estimate extracted | NR | No studies |
Time to closure ‐ not reported Duoderm® (hydroactive dressing) vs antiseptic agent | no estimate extracted | NR | No studies |
Change in ulcer size (surface area or volume) Duoderm® (hydroactive dressing) vs antiseptic agent | no estimate extracted | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported Duoderm® (hydroactive dressing) vs antiseptic agent | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Duoderm® (hydroactive dressing) vs antiseptic agent | no estimate extracted | NR | No studies |
Amputation ‐ not reported Duoderm® (hydroactive dressing) vs antiseptic agent | no estimate extracted | NR | No studies |
Adverse events Duoderm® (hydroactive dressing) vs antiseptic agent | no estimate extracted | 1 study · 35 participants | Ungraded |
Isoxuprine compared to placebo for leg ulcer in people with sickle cell disease
Population: patients with leg ulcer in people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of complete closure Isoxuprine vs placebo | no estimate extracted | 1 study · 54 participants | Very low Downgraded: risk of bias, imprecision |
Arginine butyrate plus standard local care compared to standard local care for sickle cell in people with sickle cell disease
Population: sickle cell in people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete healing Arginine butyrate plus standard local care vs standard local care | no estimate extracted | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Change in ulcer size Arginine butyrate plus standard local care vs standard local care | no estimate extracted | 1 study · 2010 participants | Very low Downgraded: risk of bias, imprecision |
L‐carnitine compared to placebo for leg ulcer in people with sickle cell disease
Population: leg ulcer in people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in ulcer size L‐carnitine vs placebo | no estimate extracted | 1 study · 15 participants | Very low Downgraded: risk of bias, imprecision |
RGD peptide matrix compared to placebo for leg ulcer in people with sickle cell disease
Population: patients with leg ulcer in people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete closure RGD peptide matrix vs placebo | no estimate extracted | 1 study · 55 participants | Very low Downgraded: risk of bias, imprecision |
Change in size ulcers healed cm2 RGD peptide matrix vs placebo | no estimate extracted | 1 study · 55 participants | Very low Downgraded: risk of bias, imprecision |
Total adverse events RGD peptide matrix vs placebo | no estimate extracted | 1 study · 55 participants | Very low Downgraded: risk of bias, imprecision |
Related study treatment adverse events RGD peptide matrix vs placebo | no estimate extracted | 1 study · 33 participants | Very low Downgraded: risk of bias, imprecision |
Isoxuprine compared to placebo for leg ulcer in people with sickle cell disease
Population: patients with leg ulcer in people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of complete closure Isoxuprine vs placebo | no estimate extracted | 1 study · 54 participants | Very low Downgraded: risk of bias, imprecision |
Arginine butyrate plus standard local care compared to standard local care for sickle cell in people with sickle cell disease
Population: sickle cell in people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete healing Arginine butyrate plus standard local care vs standard local care | no estimate extracted | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Change in ulcer size Arginine butyrate plus standard local care vs standard local care | no estimate extracted | 1 study · 2010 participants | Very low Downgraded: risk of bias, imprecision |
L‐carnitine compared to placebo for leg ulcer in people with sickle cell disease
Population: leg ulcer in people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in ulcer size L‐carnitine vs placebo | no estimate extracted | 1 study · 15 participants | Very low Downgraded: risk of bias, imprecision |
RGD peptide matrix compared to placebo for leg ulcer in people with sickle cell disease
Population: patients with leg ulcer in people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete closure RGD peptide matrix vs placebo | no estimate extracted | 1 study · 55 participants | Very low Downgraded: risk of bias, imprecision |
Change in size ulcers healed cm2 RGD peptide matrix vs placebo | no estimate extracted | 1 study · 55 participants | Very low Downgraded: risk of bias, imprecision |
Total adverse events RGD peptide matrix vs placebo | no estimate extracted | 1 study · 55 participants | Very low Downgraded: risk of bias, imprecision |
Related study treatment adverse events RGD peptide matrix vs placebo | no estimate extracted | 1 study · 33 participants | Very low Downgraded: risk of bias, imprecision |